PRINCETON, NJ, USA and SUZHOU, China I September 18, 2024 I Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated ...

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members – ...

Company symposium to highlight case reports from 11 patients with stiff-person syndrome, myasthenia gravis and multiple sclerosis reinforcing KYV-101’s initial efficacy and safety profile and broad ...

JANESVILLE, WI, USA I 18, 2024 I GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody ...

PHILADELPHIA, PA, USA I 18, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older ...

NanoVation will receive research funding and is eligible to receive up to approximately US$600 million in up-front cash and potential milestone payments, as ...

– Initiation of the second component of the Phase 1 study, in adult DMD patients, expected in Q1 2025 ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids Dr. Michael Wechsler, Professor of ...

ROCKVILLE, MD, USA I September 16, 2024 I I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for ...

EAST HANOVER, NJ, USA I 17, 2024 I Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in ...

HDT bio’s Rapid-Response Roadmap for RNA vaccines (R 4) project granted a five-year subaward for $2M per year SEATTLE, WA, USA I 17, 2024 I HDT Bio Corp., a clinical-stage biopharmaceutical company ...